What is a synthetic subprime CDO?
Six months ago I was asked to explain what a synthetic CDO was. Well pal, the sky is blue because bankers in Wall Street…. I sort of did my best and drew a few diagrams and we got about halfway there and came to a halt. I understand roughly how a synthetic CDO works, I …
Q1 2018: 10foot is up 70% FYTD
As we prepare our upcoming quarterly review, we are pleased to announce that the 10foot portfolio has returned approximately 70% since last quarter and now has an unaudited total net asset value (NAV) of $16,830 versus an initial value of $10,000 at inception. There has also been a change in the structure of the fund, …
Through a Mayne Pharma, Concisely
I put 5% of the 10foot portfolio in Mayne Pharma (ASX: MYX). My purchase thesis was way too long to be useful to readers. I have created an abbreviated version here: Mayne is undervalued given its cash earning ability Performance in FY18 will provide a much clearer picture of the combined organisation’s (post Teva/Allergan portfolio acquisition) …
Purchase #7: Mayne Pharma Group Ltd
I’ve made another purchase for the 10foot portfolio, generic pharmaceutical company Mayne Pharma Group Ltd (ASX: MYX). Mayne manufactures and sells generics, consults for third parties, sells its own specialty branded drugs, and develops new formulations for existing molecules. Mayne Pharma recently had a huge step-change in its operations after the $900m acquisition of a portfolio …
The things that move share prices
I have recently been reading through well-known investing blogs like Bronte Capital (John Hempton) and Bristlemouth (Forager/Steve Johnson) from their beginnings in 2008 or so. They are very good. I read Hempton’s in its entirety a few years ago and I would recommend his earlier posts as an excellent crash course in how the truck …
